The identification of the BCR-ABL kinase fusion protein and its role in the pathogenesis of CML has led to the emergence of BCR-ABL-targeted therapy, which has become the standard of care for patients with CML. Here, BCR is linked to chronic myelogenous leukemia, BCR-ABL1 positive.